Do watch the full-webcast [only about 27 minutes long] — note the fast track Phase III status of Vertex’s Teleprevir — and the truly upbeat assessment of its position, vis-a-vis Schering’s boceprivir. Here’s a Vertex PDF file fact sheet (see page one — center chart).
If the above-Morgan Stanley webcast won’t load — try this link, but you’ll need to sign-in.
Vertex is up another $0.25, on the NYSE, as I type this. That is all.